Larvol Delta - Caliway39s-Fat-Reduction-Drug-Candidate-CBL514-Completes-US-FDA-IND-Submission-for-Phase-2-Clinical-Study-in-Weight-Management-Expanding-Development-Combined-with-GLP1RABased-WeightLoss-Therapies

CBL-514 - Caliway Biopharmaceuticals

https://www.prnewswire.com/news-releases/caliways-fat-reduction-drug-candidate-cbl-514-completes-us-fda-ind-submission-for-phase-2-clinical-study-in-weight-management-expanding-development-combined-with-glp-1rabased-weight-loss-therapies-302649224.html

Dec 24, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next